


27. Singh RB, Singh Parmar UP, Kahale F, et al. Vaccine-associated uveitis after COVID-19 vaccination: Vaccine Adverse Event Reporting System Database Analysis. *Ophthalmology*. 2023;130(2):179–186.
28. Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. *N Engl J Med*. 2021;385(12):1078–1090.
29. Tomkins-Netzer O, Sar S, Barnett-Griness O, et al. Association between vaccination with the BNT162b2 mRNA coronavirus disease 2019 vaccine and noninfectious uveitis. *Ophthalmology*. 2022;129(10):1087–1095.
30. Hashimoto Y, Yamana H, Iwagami M, et al. Ocular adverse events after coronavirus disease 2019 mRNA vaccination: matched cohort and self-controlled case series studies using a large database. *Ophthalmology*. 2023;130(3):256–264.

## Pictures & Perspectives



### Acute Maculopathy in a Patient with Positive Coxsackie A Immunoglobulin G Viral Titers

A 23-year-old healthy woman presented with vision loss in her left eye (OS) following a prodrome consisting of fever, malaise, and maculopapular rash on her chest and shins 3 weeks prior. Visual acuity OS was 20/100, and fundus examination revealed an elevated circular area in the left macula (A) without vitritis. Fluorescein angiography (B) demonstrated speckled fluorescence pattern and pooling consistent with a neurosensory detachment. OCT (C) illustrated outer retina intraretinal fluid, subretinal fluid, and a bacillary layer detachment (arrows). Serologic testing was positive for Coxsackie A immunoglobulin G titers (titers ranged from 1:800–1:1,600; reference < 1:100) (Magnified version of Figure A-C is available online at [www.aaojournal.org](http://www.aaojournal.org)).

CHRISTINA Y. WENG, MD, MBA<sup>1,2</sup>

JIE GAO, MD<sup>1,2</sup>

BERTHA BELTRAN, COA<sup>2</sup>

<sup>1</sup>Department of Ophthalmology, Baylor College of Medicine-Cullen Eye Institute, Houston, Texas; <sup>2</sup>Department of Ophthalmology, Ben Taub General Hospital, Houston, Texas